Background: Long COVID is a heterogeneous multisystem condition associated with fatigue, cognitive difficulties, sleep disturbance, depression, anxiety, and post-traumatic symptoms.
Methods: This narrative review examined PubMed/MEDLINE literature published between January 2020 and July 2026, supplemented by major reviews and guidance from WHO, NICE, and CDC.
Results: Neuropsychiatric symptoms likely result from interacting mechanisms, including persistent immune activation, autoimmunity, endothelial dysfunction, blood–brain barrier disruption, dysautonomia, altered neurotransmitter metabolism, microbiome changes, and impaired cellular energy production. Routine investigations may be normal, and no diagnostic biomarker has been validated. Treatment remains multidisciplinary, symptom-based, and tailored to clinical phenotype, with rehabilitation adapted for post-exertional malaise.
Conclusion: Long COVID requires integrated medical, neurological, and psychiatric assessment. Further biomarker-based research and well-designed clinical trials are needed.
Sandra Kołodziejczyk, Bartłomiej Wiak, Monika Łapot et al.· African Journal of Biomedica...· 0 citations
Inflammation contributes to MDD in some patients, but single-marker diagnosis and routine anti-inflammatory treatment are not currently justified, and biomarker-stratified trials are needed to develop precision therapies.
Emilia Włoszek, Bartosz Mikołajek, Anita Godlewska et al.· African Journal of Biomedica...· 0 citations